Pemetrexed in Third and Fourth Line Chemotherapy for Non Squamous Non Small-Cell Lung CancerAlexandru Calin Grigorescu*
Department of Medical Oncology, Institute of Oncology Prof. Dr. Alexandru Trestioreanu, Bucharest, Romania
- *Corresponding Author:
- Alexandru Calin Grigorescu
Department of Medical Oncology
Institute of Oncology Prof. Dr. Alexandru Trestioreanu
E-mail: [email protected]
Received date: February 15, 2017; Accepted date: February 27, 2017; Published date: March 06, 2017
Citation: Grigorescu AC (2017) Pemetrexed in Third and Fourth Line Chemotherapy for Non Squamous Non Small-Cell Lung Cancer. J Integr Oncol 6:187. doi: 10.4172/2329-6771.1000187
Copyright: © 2017, Grigorescu AC. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Introduction: Lung cancer is responsible for the highest mortality caused by malignant solid tumors. Chemotherapy remains one of the most important modality of treatment. Methods: This retrospective study analyzed the records of 42 patients’ treatment with pemetrexed, used in second, third and fourth line chemotherapy for advanced non-squamous non-small cell cancer (NSCLC). Kaplan Meier curve was used for calculation of overall survival. Results: The median overall survival in the second-line was 10 months and in third- and fourth-line was 6.5 months. Discussion: We discuss the similar study with pemetrexed in mono-chemotherapy or combination, study with similar results. Also we make a reference to the new therapy with best results but with much higher cost and effective only for a part of patients. Conclusions: This result and other results presented in similar studies encourage us to recommend pemetrexed in the third and fourth line chemotherapy for well-selected patients.